303 related articles for article (PubMed ID: 18342006)
1. The DNA sugar backbone 2' deoxyribose determines toll-like receptor 9 activation.
Haas T; Metzger J; Schmitz F; Heit A; Müller T; Latz E; Wagner H
Immunity; 2008 Mar; 28(3):315-23. PubMed ID: 18342006
[TBL] [Abstract][Full Text] [Related]
2. The sweetness of the DNA backbone drives Toll-like receptor 9.
Wagner H
Curr Opin Immunol; 2008 Aug; 20(4):396-400. PubMed ID: 18656540
[TBL] [Abstract][Full Text] [Related]
3. CpG motif-independent activation of TLR9 upon endosomal translocation of "natural" phosphodiester DNA.
Yasuda K; Rutz M; Schlatter B; Metzger J; Luppa PB; Schmitz F; Haas T; Heit A; Bauer S; Wagner H
Eur J Immunol; 2006 Feb; 36(2):431-6. PubMed ID: 16421948
[TBL] [Abstract][Full Text] [Related]
4. Negative regulation of TLR9-mediated IFN-alpha induction by a small-molecule, synthetic TLR7 ligand.
Marshall JD; Heeke DS; Gesner ML; Livingston B; Van Nest G
J Leukoc Biol; 2007 Sep; 82(3):497-508. PubMed ID: 17565046
[TBL] [Abstract][Full Text] [Related]
5. Oligodeoxyribonucleotide-based antagonists for Toll-like receptors 7 and 9.
Wang D; Bhagat L; Yu D; Zhu FG; Tang JX; Kandimalla ER; Agrawal S
J Med Chem; 2009 Jan; 52(2):551-8. PubMed ID: 19102653
[TBL] [Abstract][Full Text] [Related]
6. Toll-like receptor 9 binds single-stranded CpG-DNA in a sequence- and pH-dependent manner.
Rutz M; Metzger J; Gellert T; Luppa P; Lipford GB; Wagner H; Bauer S
Eur J Immunol; 2004 Sep; 34(9):2541-50. PubMed ID: 15307186
[TBL] [Abstract][Full Text] [Related]
7. Activation of invariant NKT cells by toll-like receptor 9-stimulated dendritic cells requires type I interferon and charged glycosphingolipids.
Paget C; Mallevaey T; Speak AO; Torres D; Fontaine J; Sheehan KC; Capron M; Ryffel B; Faveeuw C; Leite de Moraes M; Platt F; Trottein F
Immunity; 2007 Oct; 27(4):597-609. PubMed ID: 17950005
[TBL] [Abstract][Full Text] [Related]
8. Baseless assumptions: activation of TLR9 by DNA.
Gangloff M; Gay NJ
Immunity; 2008 Mar; 28(3):293-4. PubMed ID: 18342000
[TBL] [Abstract][Full Text] [Related]
9. Ligand-induced conformational changes allosterically activate Toll-like receptor 9.
Latz E; Verma A; Visintin A; Gong M; Sirois CM; Klein DC; Monks BG; McKnight CJ; Lamphier MS; Duprex WP; Espevik T; Golenbock DT
Nat Immunol; 2007 Jul; 8(7):772-9. PubMed ID: 17572678
[TBL] [Abstract][Full Text] [Related]
10. TLR9 signals after translocating from the ER to CpG DNA in the lysosome.
Latz E; Schoenemeyer A; Visintin A; Fitzgerald KA; Monks BG; Knetter CF; Lien E; Nilsen NJ; Espevik T; Golenbock DT
Nat Immunol; 2004 Feb; 5(2):190-8. PubMed ID: 14716310
[TBL] [Abstract][Full Text] [Related]
11. The immunostimulatory activity of unmethylated and methylated CpG oligodeoxynucleotide is dependent on their ability to colocalize with TLR9 in late endosomes.
de Jong SD; Basha G; Wilson KD; Kazem M; Cullis P; Jefferies W; Tam Y
J Immunol; 2010 Jun; 184(11):6092-102. PubMed ID: 20427776
[TBL] [Abstract][Full Text] [Related]
12. Role of atopic status in Toll-like receptor (TLR)7- and TLR9-mediated activation of human eosinophils.
Månsson A; Cardell LO
J Leukoc Biol; 2009 Apr; 85(4):719-27. PubMed ID: 19129482
[TBL] [Abstract][Full Text] [Related]
13. TLR9/TLR7-triggered downregulation of BDCA2 expression on human plasmacytoid dendritic cells from healthy individuals and lupus patients.
Wu P; Wu J; Liu S; Han X; Lu J; Shi Y; Wang J; Lu L; Cao X
Clin Immunol; 2008 Oct; 129(1):40-8. PubMed ID: 18684674
[TBL] [Abstract][Full Text] [Related]
14. UNC93B1 delivers nucleotide-sensing toll-like receptors to endolysosomes.
Kim YM; Brinkmann MM; Paquet ME; Ploegh HL
Nature; 2008 Mar; 452(7184):234-8. PubMed ID: 18305481
[TBL] [Abstract][Full Text] [Related]
15. Regulatory molecules required for nucleotide-sensing Toll-like receptors.
Saitoh S; Miyake K
Immunol Rev; 2009 Jan; 227(1):32-43. PubMed ID: 19120473
[TBL] [Abstract][Full Text] [Related]
16. Intracellular localization of Toll-like receptor 9 prevents recognition of self DNA but facilitates access to viral DNA.
Barton GM; Kagan JC; Medzhitov R
Nat Immunol; 2006 Jan; 7(1):49-56. PubMed ID: 16341217
[TBL] [Abstract][Full Text] [Related]
17. Emerging roles of TLR7 and TLR9 in murine SLE.
Santiago-Raber ML; Baudino L; Izui S
J Autoimmun; 2009; 33(3-4):231-8. PubMed ID: 19846276
[TBL] [Abstract][Full Text] [Related]
18. Structure-activity relationship studies on the immune stimulatory effects of base-modified CpG toll-like receptor 9 agonists.
Jurk M; Kritzler A; Debelak H; Vollmer J; Krieg AM; Uhlmann E
ChemMedChem; 2006 Sep; 1(9):1007-14. PubMed ID: 16952134
[TBL] [Abstract][Full Text] [Related]
19. Synthetic agonists of Toll-like receptors 7, 8 and 9.
Agrawal S; Kandimalla ER
Biochem Soc Trans; 2007 Dec; 35(Pt 6):1461-7. PubMed ID: 18031246
[TBL] [Abstract][Full Text] [Related]
20. Molecular cloning and characterization of equine Toll-like receptor 9.
Zhang YW; Davis EG; Blecha F; Wilkerson MJ
Vet Immunol Immunopathol; 2008 Aug; 124(3-4):209-19. PubMed ID: 18462806
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
